
Sydbank senior analyst Søren Løntoft Hansen expects Genmab to upgrade its total predicted market sales for 2021 after Johnson & Johnson's Q2 sales figures for Darzalex were revealed on Wednesday.
In the second quarter of this year, Johnson & Johnson sold USD 1.43bn worth of Darzalex, which is developed by Genmab. During the corresponding period last year, the US pharmaceutical company's Darzalex sales totaled USD 901m, meaning sales growth over the past year equates to 59.2 percent.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app